The orodispersible tablet (ODT) technology offers advantages over the traditional dosage formulations as they allow easy swallowing without the use of water in paediatrics and geriatrics patient populations.

This technology is advantageous to patients suffering from diseases, such as mouth cancer, where swallowing the drug is a challenge. Global drug giant Merck has launched ODT technologies for delivery of water-insoluble compounds with robust in-vivo performance.